![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, June 11, 2020 2:35:18 PM
Still nothing commercialized.
• First product line - internally developed Human Cell and Tissue Products - launched in 2017
Yep nothing much in sales threw away more product in the last 2 qrts. than they sold.
• Launched 2 novel, genetic-based endometriosis and fertility diagnostic/prognostic tests in Dec. 2018
UMM where's the sales then if they launched them? Art-guide is still doing retrograde studies.
• Broad, follow-on pipeline of diagnostics and therapeutics in the near-, mid-, and longterm.
Yes Atrin deal. Still have hope they might make some money on that in a few years.
• Cash positive operating position with no debt (only operating payables)
$250k on hand as of last month, $1.7 mill gov't loan to stay afloat. MULTI-Millions in debt. $551k lawsuit for non-payment of services.
• Pursuing a near-term NASDAQ listing
NOPE delisted 2x persuiting to stay in business and to get back to stink pinkies. As of now stuck in gray land for how long????
How much has changed for the worse in past 12 months.
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM